# Firdapse for Post-BOTOX Vocal Weakness

> **NCT05123053** · PHASE2 · COMPLETED · sponsor: **Augusta University** · enrollment: 18 (actual)

## Conditions studied

- Vocal Weakness(Post-BOTOX Injection)

## Interventions

- **DRUG:** Amifampridine

## Key facts

- **NCT ID:** NCT05123053
- **Lead sponsor:** Augusta University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-28
- **Primary completion:** 2025-05-27
- **Final completion:** 2025-09-23
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2025-10-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05123053

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05123053, "Firdapse for Post-BOTOX Vocal Weakness". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05123053. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*